Blue Mountain and RCM Technologies Partner to Elevate Enterprise Asset Management in Life Sciences with Pre-Validated Software and Unparalleled Domain Expertise
05 sept. 2024 09h00 HE
|
Blue Mountain
Blue Mountain & RCM Technologies join forces to deliver cutting-edge EAM solutions, tailored for life sciences with pre-validated software & expert service
Yseop Joins Veeva’s AI Partner Program to Accelerate Regulatory Document Writing and AI-Driven Content Automation
05 sept. 2024 09h00 HE
|
Yseop
NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Yseop, a leader in artificial intelligence (AI) enterprise software, is excited to announce it has joined the Veeva AI Partner Program. As a Veeva AI...
Monthly information on share capital and company voting rights
04 sept. 2024 16h30 HE
|
Cellectis Inc.
PARIS, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...
Inaugural Pre-JPM Partnering Week to Wrap Up 2024, Prepare for 2025
29 août 2024 07h30 HE
|
Big4Bio
New life science partnering conference to debut that prepares and helps industry dealmakers and stakeholders for the JP Morgan Healthcare Conference week
Lifecore Biomedical Announces Chief Financial Officer Transition
29 août 2024 07h00 HE
|
Lifecore Biomedical, Inc.
CHASKA, Minn., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization...
Lipella Pharmaceuticals to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York
27 août 2024 08h00 HE
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York
Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research
22 août 2024 05h00 HE
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research
NurExone Biologic Achieves Key Milestone in Support of Robust Exosome Manufacturing Process
15 août 2024 16h03 HE
|
NurExone Biologic Inc
NurExone’s reliable production from diverse biological sources allows NurExone to optimize exosome production with consistency and efficiency
NurExone's ExoPTEN, loaded with siRNA, Demonstrates Ability to Target Injury and Inflammation Sites – New Study
09 août 2024 16h04 HE
|
NurExone Biologic Inc
NurExone announces promising new data for its ExoPTEN nanodrug, highlighting progress towards commercial-grade manufacturing
Monthly information on share capital and company voting rights
05 août 2024 16h30 HE
|
Cellectis Inc.
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number...